News and Research


MARCH 2016

iTP Biomedica’s clinical partner receives CAP accreditation for the BladderPredict bladder cancer diagnostic test to support distribution throughout North America


iTP Biomedica Corp. secured funding provided by the Government of Ontario through the Ontario Centres of Excellence (“OCE”). This financing was through that OCE’s Market Readiness CC (MRII) program. OCE is a member of the Ontario Network of Entrepreneurs (“ONE”)


Liu Y, Noon AP, Aguiar Cabeza E, Shen J, Kuk C, Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, Hermanns T, Blencowe BJ, Azad A, van der Kwast TH, Catto JW, Zlotta AR, Wrana JL. Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. Eur Urol. 2014 Dec;66(6):982-6.

Noon A, Liu Y, Shen J, Kuk C, Hermanns T, Azad A, Sweet J, Comperat E, van der Kwast TH, Catto JWF, Zlotta AR, Wrana JL. Resolving Inter-Pathologist Variation in the Assignment of Grade Using Whole Transcriptome Analysis for Patients with Urothelial Bladder Cancer. J Urol. 2015

Shen J., Noon A., Aguiar Cabeza E., Kuk C., Ilczynski C., Ni R., Sukhu B., Chan K., Gunaratne A., Erlich A., Cremer C., Morris Q., Barbosa-Morais N., Roupret M., Compérat E., Sweet J., Fleshner N., Kulkarni G., Blencowe B., Azad A., Van Der Kwast T., Zlotta A.R., Wrana J. Molecular tumor grading of non muscle invasive bladder cancer based on whole transcriptome analysis.  (abst: PD11-09)

  • J. of Urol. 2016. 195(4): e291.
  • ASC University. GU ASCO 2016.
  • Oncol. 34, 2016 (suppl 2S; abst 467)
  • European Urology Supplements. 15(3): March 2016 (abst: 746)